Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 113 Show results per page	View Search Criteria \| Help With Results


1.		Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				CSTI571AUS177 US177, RIGHT Trial, NCT00081926


2.		Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				20 to 74				Pharmaceutical / Industry				CSTI571BJP07 NCT00171977


3.		Study Comparing Standard Dose and High-Dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				CSTI571ACA09 NCT00171899


4.		Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CSTI571H2201 NCT00290771


5.		Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CSTI571H2202 NCT00292149


6.		Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA180-043 EUDRACT Number: 2005-005153-22, NCT00320190

Last Modified: 12/8/2006 First Published: 10/1/2000


7.		Phase III Randomized Study of STI571 vs Interferon Alfa and Cytarabine in Patients With Newly Diagnosed, Previously Untreated, Philadelphia Chromosome Positive, Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70				NCI, Pharmaceutical / Industry				NOVARTIS-CSTI5710106 FHCRC-1556.00, NCT00006343

Last Modified: 5/19/2008 First Published: 2/1/2001


8.		Phase III Randomized Study of Two Different Doses of Imatinib Mesylate in Patients With CD117-Expressing Metastatic or Unresectable Gastrointestinal Stromal Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 and over				NCI				CLB-80004 CAN-NCIC-S0033, E-S0033, SWOG-S0033, INT-S0033, NCT00009906, S0033

Last Modified: 8/28/2008 First Published: 7/1/2002


9.		A Phase III Randomized Double-Blind Study of Adjuvant Imatinib Mesylate (Gleevec; STI571) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ACOSOG-Z9001 CAN-NCIC-SRC1, CALGB-ACOSOG-Z9001, SWOG-ACOSOG-Z9001, ACOSOG-Z9001, NCT00041197, UWCC-UW-6303, UWCC-UW-03-8438-A-03, SRC1

Last Modified: 4/4/2008 First Published: 2/1/1993


10.		Phase III Randomized Study of Allogeneic or Autologous Stem Cell Transplantation Versus Conventional Consolidation and Maintenance Chemotherapy in Patients With Acute Lymphoblastic Leukemia in First Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				15 to 65				NCI				ECOG-2993 MRC-LEUK-UKALL-XII, EST-4491, INT-0132, NCT00002514

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute